Financial Results - Quarter Ended September 30, 2026

Revenue Performance:

  • Revenue from operations: ₹11,223 million ($117.5 million)
  • Year-over-Year (YoY) growth: 39.5% in INR, 27.5% in USD
  • Quarter-over-Quarter (QoQ) growth: 5.6% in INR, 4.4% in USD

Profitability Metrics:

  • EBITDA: ₹1,873 million
  • EBITDA margin: 16.7%
  • EBITDA YoY growth: 32.0%
  • Profit After Tax (PAT): ₹1,123 million
  • PAT margin: 10.0%
  • PAT YoY growth: 10.0%

Comparative Financial Performance

| Particulars | Sep 30, 2026 | Jun 30, 2026 | Sep 30, 2025 |

| Revenue (₹M) | 11,223 | 10,631 | 8,042 |

| Revenue ($M) | 117.5 | 112.5 | 92.2 |

| YoY growth (%) | 39.5% | 39.7% | 17.1% |

| EBITDA (₹M) | 1,873 | 1,795 | 1,419 |

| EBITDA margin (%) | 16.7% | 16.9% | 17.6% |

| PAT (₹M) | 1,123 | 1,162 | 1,021 |

| PAT margin (%) | 10.0% | 10.9% | 12.7% |

Operational Highlights

Client Metrics:

  • Customers generating $1M+ annual revenue: 59 (increased by 5 sequentially)
  • Customers in $10M+ range: 13

Efficiency Metrics:

  • Revenue per Employee (RPE): $79.6K (described as highest among peers)

Business Development:

  • Growth described as broad-based, driven by expansion across top 5 and top 20 accounts
  • Significant deal wins in GenAI-enabled transformation and upstream engagements

Management Commentary

Manish Gupta, Chairman and CEO:

  • Described Q2 as extending strong start to FY27 with fifth successive quarter above 5% sequential growth
  • Cited healthy pipeline, sustained deal momentum and favourable industry tailwinds
  • Expects growth and margin expansion to come together in the second half

Suhas Prabhu, CFO:

  • Noted EBITDA margin remained stable at 16.7% despite annual wage increase effective in Q2
  • PAT grew 10% YoY to ₹1,123 million
  • Expects EBITDA to grow faster than revenue in coming quarters with wage increase fully reflected
  • Expects higher yields on investments and lower amortization to help PAT margin expand faster than EBITDA margin

Additional Information

Regulatory Reference: SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regulation 30 read-with Schedule III

Document Availability: Filed with BSE Limited and National Stock Exchange of India Limited. Also available on company website at https://www.indegene.com/

Company Description: Indegene Limited is described as the strategic operating partner to the global life sciences industry, orchestrating commercial, medical, R&D, and safety operations across the product lifecycle. The company serves top 20 biopharma companies and combines deep life sciences expertise with AI-embedded platforms.

Contact Information:

  • Investor inquiries: IR@indegene.com
  • Media inquiries: yadunandan.kv@indegene.com